ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Avigan fails to prove COVID efficacy in U.S. trials, in blow to Fujifilm

Company will continue efforts in Japan, but path to American market looks closed

Fujifilm and its partner had hoped to request emergency use authorization of Avigan as a COVID-19 treatment as early as this year. 

TOKYO -- Fujifilm Holdings' flu-fighting drug Avigan failed to prove sustained clinical recovery from COVID-19 in a test conducted by a Canadian partner in the U.S., Mexico and Brazil, significantly hampering its chances of implication in the American market.

Appili Therapeutics, the Halifax-based partner, said the Phase 3 clinical trial evaluating oral antiviral Avigan for the treatment of mild to moderate COVID-19 "did not achieve statistical significance on the primary endpoint of time to sustained clinical recovery." Additional analyses of the trial data are ongoing, the company said in a news release Friday.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more